Patients are sidestepping clinical research and using themselves as guinea pigs to test new treatments for fatal diseases. Will they hurt themselves, or science?
The FDA approves an antibody-drug conjugate that effectively treats a certain type of advanced breast cancer with fewer side effects than previous drugs.
The first human trial of a treatment using induced pluripotent stem cells has received conditional approval from an institutional review board in Japan.
One of the most advanced tuberculosis vaccines has failed to protect infants from getting the disease in a clinical trial, but it may be effective in adults.
Academics get paid handsome fees to consult with the financial industry, but run the risk of revealing confidential information that leads to illicit gains.
The malaria vaccine under development by GSK and the PATH initiative only protects about one in three babies, though some researchers say those odds are better than nothing.
A large-scale statistical analysis shows that medical studies revealing “very large effects” seldom stand up when other researchers try to replicate them.
Another clinical trial raises concerns about the efficacy and safety of a common intravenous treatment for patients that have lost large amounts of blood.